[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100172620":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":29,"locations":38,"responsibleParty":51,"collaborators":19,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":19,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":19,"overallStatus":41,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort study","OTHER","Blood sampling",[13],"Biological: blood sampling",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","blood sampling",[9],null,[21,25],{"name":22,"affiliation":23,"role":24},"Olivier Lambotte, Professor","Kremlin Bicetre","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":27,"role":28},"Laurence Meyer, Professor","Methodologist INSERM CESP U1018","STUDY_CHAIR",[30,34],{"name":22,"role":31,"phone":32,"phoneExt":19,"email":33},"CONTACT","01 49 59 67 54","olivier.lambotte@bct.aphp.fr",{"name":35,"role":31,"phone":36,"phoneExt":19,"email":37},"Faroudy Boufassa","01 45 21 23 65","faroudy.boufassa@inserm.fr",[39],{"facility":40,"status":41,"city":42,"state":19,"zip":19,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":19},"Lambotte","RECRUITING","Le Kremlin-Bicêtre","France","FR",{"type":46,"coordinates":47},"Point",[48,49],2.36073,48.81471,{"lat":49,"lon":48},{"type":52,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100172620","the-anrs-co21--extreme--cohort-codex-100172620",false,"NCT01520844","the ANRS CO21 \" Extreme \" Cohort (CODEX)","Multicentric Cohort of HIV Patient With Extrem Profil","CODEX","Inclusion Criteria:\n\n* Patient infected with HIV-1 and not co-infected with HIV-2\n* Age ≥ 18 at enrollment\n* Able to give written consent\n* Covered by French Social Security\n* accept the constraints imposed by the study\n* without antiretroviral therapy for ALT, HIC and ALT HIC groups and a control of viral load after antiretroviral treatment interruption in PTC group\n\nALT group: Documented HIV-1 seropositive for at least 8 years with a CD4 count above 600\u002Fmm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years regardless of the viral load in the absence of antiretroviral treatment\n\nHIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the last 5 viral loads in HIV-RNA consecutive \\\u003C400 copies \u002F mL regardless of CD4 count in the absence of antiretroviral treatment\n\nALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater than 600\u002Fmm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years and with the last 5 viral loads in HIV-RNA consecutive \\\u003C400 copies \u002F mL in the absence of antiretroviral therapy.\n\nPTC group: Patients with plasma HIV RNA \\> 2000 copies\u002FmL before initiation of antiretroviral therapy. Treatment started during the primary infection (as defined by symptoms associated with seroconversion, as confirmed by a first negative ELISA and\u002For an incomplete P24-positive Western blot) or during the chronic phase of infection, and maintained for at least 12 months in both cases. Control of viral load after antiretroviral treatment interruption: patients must have at least two available viral load assays after stopping antiretroviral therapy. All viral loads must be \\\u003C400 copies\u002FmL for 12 months or more after stopping antiretroviral therapy, with the possible exception of one blip (one viral load above 400 copies\u002FmL between two viral loads \\\u003C400 copies\u002FmL at least one month apart from the blip; in this case at least three viral load assays will be required). The last plasma viral load value at the time of inclusion must always be \\\u003C400 copies\u002FmL\n\nExclusion Criteria:\n\nUnder protection(saving) of justice","ALL","18 Years","85 Years",{"count":65,"type":66},450,"ESTIMATED","INTERVENTIONAL",[69],"NA","A consortium of research teams has studied the immunovirological characteristics of these patients:\n\nThe ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study",[72],"HIV Infection","2026-04-02",{"date":75,"type":76},"2026-04-07","ACTUAL",{"date":78,"type":76},"2012-02",{"date":80,"type":66},"2030-09",{"name":5,"class":6},1]